FDA clears Surefire's Angiographic Catheter line

NewsGuard 100/100 Score

Surefire Medical, Inc. announced today that the company has received 510(k) FDA clearance to market its line of Surefire Angiographic Catheters. Surefire Medical will launch these products in the United States later this year.

Surefire's Angiographic Catheter line is designed to provide interventional radiologists with far greater flexibility and the highest level of trackability when performing infusion procedures. With a large inner lumen of 0.054 inches, the Surefire Angiographic catheters will be available in a variety of different curve styles for accessing a wide range of patient anatomies.

Interventional radiologists pioneered and continue to specialize in minimally invasive, targeted treatments that once required surgery. They offer the most in-depth knowledge of the least invasive treatments available, coupled with diagnostic and clinical experience across all specialties, according to the Society of Interventional Radiology (SIR).

"Surefire designed our line of Angiographic Catheters to help advance interventional radiology procedures by providing optimal diagnostic imaging and detail during infusion procedures," said Jim Chomas, CEO of Surefire Medical. "We are excited to offer a suite of products to better meet their clinical needs. Further, the large inner lumen provides a new level of flexibility to these physicians."

This is the third FDA 510(k) clearance received by Surefire Medical since July 2011. The company also received FDA 510(k) clearance for its Surefire Infusion System and Surefire's new ST and LT infusion systems, which greatly increase the efficiency of targeted treatments. In addition, Surefire received CE Mark for the Surefire Infusion System in August 2012.

Source:

Surefire Medical, Inc.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New cryoablation technique eliminates ventricular tachycardia in 94% of patients